1 / 6

Hemophilia Therapeutics Pipeline to Witness Major Collaborations in The Future

Many Drug Candidates Received Orphan, Fast Track or Breakthrough Designations for The Treatment of Hemophilia

NidhiNehani
Download Presentation

Hemophilia Therapeutics Pipeline to Witness Major Collaborations in The Future

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hemophilia Therapeutics Pipeline to Witness Major Collaborations in The Future

  2. Hemophilia Therapeutics Pipeline Analysis According to a new research report “Hemophilia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Hemophilia currently exhibits a strong pipeline with 53 drug candidates. Browse Report Description at:https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis Hemophilia pipeline in 2017 The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development.

  3. Hemophilia Therapeutics Pipeline Analysis Insights on pipeline segments The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route. Increasing collaboration between educational institutes, medical associations and pharma companies Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In September 2016, Roche in collaboration with Chugai Pharmaceutical Co. Ltd. initiated a Phase III trial to evaluate the safety, pharmacokinetics and efficacy of prophylactic subcutaneous emicizumab in patients (aged 12 years) suffering from hemophilia A without factor VIII inhibitors.

  4. Hemophilia Therapeutics Pipeline Analysis Various drug candidates received, Fast Track or Breakthrough Designation for the treatment of hemophilia Many drug candidates received USFDA designations namely Orphan, Fast Track or Breakthrough designations in their clinical stages for the treatment of hemophilia. In August 2016, Orphan Drug Designation was granted to Phase III drug candidate of Chugai Pharmaceuticals, by Ministry of Health, Labour and Welfare, Japan. Some of the key players developing drugs for the treatment of hemophilia include SangamoBioSciences, Inc., Caisson Biotech, Inc., XL-protein GmbH, and others.

  5. Hemophilia Therapeutics Pipeline Analysis Download report sample at: https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related